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Introduction
============

Adverse cutaneous events can occur in vaccine injection sites \[[@REF1]\]. These include inflammatory reactions and neoplasms. We describe a woman who developed a cellular blue nevus at the site of previous tetanus, diphtheria, and acellular pertussis (Tdap) injection. Cutaneous reactions to combined tetanus, diphtheria, and acellular pertussis vaccines and adverse skin reactions and neoplasms appearing in previous sites of vaccinations are also reviewed.

Case presentation
=================

A 54-year-old woman presented with a new lesion on her left arm. Four years prior to presentation, an acquaintance of the patient developed pertussis, which prompted the patient to seek immunization. The patient had not been vaccinated against pertussis in childhood. Based on the Center for Disease Control age recommendations, Tdap was administered on her left deltoid; the patient subsequently developed a new lesion over the previous site of the vaccine administration.

Cutaneous examination revealed a 5 x 5 mm papule on her prior Tdap vaccination site (Figure [1](#FIG1){ref-type="fig"}). A punch biopsy was performed. Microscopic examination showed ovoid melanocytes in the dermis. Collagen was trapped between the melanocytes and the surrounding fibrous stroma.

![Cellular blue nevus appearing at the site of previous tetanus, diphtheria, and acellular pertussis (Tdap) vaccination\
Distant (a) and closer (b) views of the deltoid area of the left arm of a 54-year-old woman showing a cellular blue nevus (black arrow) that developed at the site of a previous tetanus, diphtheria, and acellular pertussis (Tdap) vaccination that she received four years earlier.](cureus-0011-00000004997-i01){#FIG1}

Correlation of the clinical history, lesion morphology, and pathology established the diagnosis of a cellular blue nevus developing at the site of the Tdap vaccination. The residual lesion was excised. There has been no recurrence.

Discussion
==========

The first vaccination against pertussis, also commonly called "whooping cough," was formulated using killed whole-cell *Bordetella pertussis* bacilli and licensed in 1914 \[[@REF2]\]. Currently, there is no isolated vaccination for pertussis. Combination vaccines containing diphtheria toxoids, tetanus toxoids, and chemically-inactivated whole-cell pertussis were introduced as DTP in the 1940s; the acronym DTP was based on the first letter of each respective component. Subsequently, based on concerns regarding the adverse reactions to inactivated whole-cell pertussis, researchers developed an acellular vaccination for pertussis immunity; this vaccination came into wider use in the 1990s in the United States as the combined diphtheria, tetanus, and acellular pertussis vaccination (DTaP) \[[@REF2]-[@REF3]\].

The DTaP vaccination did not maintain adequate long-term humoral immunity against pertussis \[[@REF4]\]. Therefore, a booster formulation of tetanus toxoid and smaller concentrations of the diphtheria toxoid and acellular pertussis received the approval from the Federal Drug Administration in 2005 as Tdap. Both DTaP and Tdap are currently in use. According to the United States Center for Disease Control, in children under seven years of age, DTaP is recommended, whereas for older children and for adults who have never been vaccinated, the Tdap is recommended \[[@REF5]\].

Numerous cutaneous reactions have been observed at the sites of both live and attenuated vaccinations. These reactions include not only inflammatory reactions such as lichenoid and granulomatous dermatosis, but also neoplasms such as basal cell carcinoma, dermatofibrosarcoma protuberans, and squamous cell carcinoma (Table [1](#TAB1){ref-type="table"}, Table [2](#TAB2){ref-type="table"}) \[[@REF1]\]. Skin-related reactions specific to diphtheria, tetanus, and pertussis vaccination include deep reactive nodular infiltrates of mixed inflammation, *Mycobacterium tuberculosis* abscess, and necrotizing granuloma (Table [3](#TAB3){ref-type="table"}) \[[@REF6]-[@REF7]\]. The development of benign or malignant neoplasms at prior sites of vaccination may be coincidental.

###### Benign cutaneous lesions associated with vaccination sites

BCG = Bacillus Calmette-Guerin vaccine; DRNIMI = Deep reactive nodular infiltrates of mixed inflammation; DTaP-IPV-Hib = Diphtheria, tetanus, pertussis, polio, Haemophilus influenzae Type B vaccine; DPT = Diphtheria, whole-cell pertussis, and tetanus vaccine; DTP = Diphtheria, tetanus, and whole-cell pertussis vaccine; ESM = Early summer meningitis vaccine; Flu = Influenza vaccine; HepB = Hepatitis B vaccine; PLAPR = Papulonodular lichenoid and pseudolymphomatous reaction; Pne = Pneumococcal vaccine; Sp = Smallpox vaccine; Td = Tetanus and diphtheria vaccine; Tdap-IPV = Tetanus, diphtheria, pertussis, and polio vaccine; Tet = Tetanus vaccine; VZV = Varicella-zoster virus vaccine

^a^Robust take is a skin reaction at the site of administration greater than 7.5 cm in size with symptoms of joint pain, swelling, and warmth.

  ------------------------------------------------- ---------------------
  Cutaneous lesions                                 Vaccination
  Abscess or cellulitis                             BCG, Pne
  Allergic contact dermatitis                       Sp
  Angiolymphoid hyperplasia with eosinophils        Tet
  Blistering                                        BCG
  Churg-Strauss vasculitis                          HepB
  DRNIMI                                            DTP
  Dermatitis, chronic                               Sp
  Dermatofibroma                                    Sp
  Epithelial cyst                                   BCG
  Erythema                                          BCG, HepB, Pne, VZV
  Fixed drug eruption                               BCG
  Foreign body granuloma (non-necrotizing)          BCG
  Granuloma annulare                                BCG, HepB, Td, Tet
  Granuloma (delayed)                               BCG
  Herpes simplex virus infection                    Sp
  Indurated erythematous plaque (pseudoplymphoma)   Tet
  Inflammatory reaction, localized                  Sp
  Itching granuloma                                 Pne, DTaP-IPV-Hib
  Isotopic response to patch testing                BCG
  Keloid                                            BCG, HepB, Sp
  Lichenoid dermatitis                              Pne
  Lupus erythematosus (discoid)                     Sp
  Lupus vulgaris (cutaneous tuberculosis)           BCG
  Lymphadenopathy (suppurative)                     BCG
  Mastocytoma                                       HepB
  Mycobacterium chelonae abscess                    Tdap-IPV
  Mycobacterium tuberculosis abscess                DPT
  Myxedematous infiltration, diffuse                Sp
  Necrobiotic granuloma                             HepB
  Necrotizing granulomatous reaction                BCG, DTP
  Nevus sebaceous                                   Sp
  Nodules                                           HepB
  Papular tuberculids                               BCG
  PLAPR                                             HepB
  Pigmentation                                      Sp
  Pilomatricoma                                     BCG
  Post scab lesions                                 Sp
  Progressive vaccinia                              Sp
  Psoriasis                                         BCG, Flu
  Pyogenic infections                               Sp
  Robust take^a^                                    Sp
  Sarcoidosis (juvenile)                            BCG
  Subcutaneous nodule (sterile abscess)             DTaP-IPV-Hib
  Subcutaneous nodule (pseudolymphoma)              ESM, HepB, VZV
  Sweet's syndrome                                  BCG, Flu, Pne, Sp
  Tufted angioma                                    BCG
  Ulceration                                        BCG
  Ulceration during Kawasaki disease                BCG
  Vasculitis (ulcerating)                           BCG
  Zosteriform eruption                              VZV
  ------------------------------------------------- ---------------------

###### Neoplasms associated with vaccination sites

BCG = Bacillus Calmette-Guerin vaccine; Lsh = Leishmaniasis vaccine; Pne = Pneumococcal vaccine; Sp = Smallpox vaccine; TPY = Tetanus, plague, yellow fever vaccine

  --------------------------------- -----------------------------------
  Cutaneous lesions                 Vaccination
  Basal cell carcinoma              BCG, Sp
  Dermatofibrosarcoma protuberans   Lsh, Sp, TPY, Travel immunization
  Fibrosarcoma                      Sp
  Keratoacanthoma                   Pne, Sp
  Malignant fibrous histiocytoma    Sp
  Melanoma                          Sp
  Squamous cell carcinoma           BCG, Sp
  --------------------------------- -----------------------------------

###### Combined tetanus, diphtheria, and pertussis vaccine site reactions

CR = Current report; DRNIMI = Deep reactive nodular infiltrates of mixed inflammation; DPT = Diphtheria, whole-cell pertussis, and tetanus vaccine; DTP = Diphtheria, tetanus, and whole-cell pertussis vaccine; Tdap = Tetanus, diphtheria, and acellular pertussis vaccine

^a^The cited reference refers to the combined diphtheria, whole-cell pertussis, and tetanus vaccination as "DPT," which is an alternative acronym for DTP.

  -------------------------------------- ------------- -------------
  Reaction                               Vaccination   Reference
  Abscess (Mycobacterium tuberculosis)   DPT^a^        \[[@REF6]\]
  Blue nevus                             Tdap          CR
  DRNIMI                                 DTP           \[[@REF7]\]
  Necrotizing granuloma                  DTP           \[[@REF7]\]
  -------------------------------------- ------------- -------------

Our patient developed a cellular blue nevus on the site of the injection after she received a Tdap vaccination \[[@REF8]\]. To the best of our knowledge, she is the only person who has developed a vaccination site-related blue nevus. In addition, we are not aware of any other individuals developing a melanocytic lesion at the site of Tdap vaccination.

A postulated pathogenesis for the formation of a new cutaneous disease at a site of prior cutaneous insult has been attributed to the creation of an "immunocompromised district"-a localized site of immune destabilization in the skin leading to increased risk of developing dermatoses \[[@REF9]\]. Through this potential mechanism, vaccination administration may allow the site to be more prone to developing a wide array of skin conditions. The appearance of our patient's cellular blue nevus following localized skin trauma from the vaccination may be the etiology of this phenomenon.

The administration of vaccinations is extremely common. The development of cutaneous adverse reactions at the site of vaccination is a rare occurrence. Although the rate for cutaneous adverse reactions at the vaccination sites remains to be established, the estimated rate would be very low based on the published literature of these events.

Conclusions
===========

Adverse events may occur in local vaccination sites. Our patient developed a cellular blue nevus at the site of the Tdap vaccine administration. The development of a melanocytic nevus at the site of Tdap vaccination has not been previously described as a post-vaccination sequela. We suggest that this vaccination site-related tumor may have resulted from the creation of a local immunocompromised district in the skin following Tdap vaccination.
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